Phentermine-d5 (hydrochloride) (CRM)
目录号 : GC48938
A Certified Reference Material
Cas No.:1330236-21-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Phentermine-d5 (CRM) is intended for use as an internal standard for the quantification of phentermine by GC- or LC-mass spectrometry. Phentermine is an α-methylated amphetamine that activates trace amine associated receptor 1 (TAAR1, EC50 = 5.47 µM).1 It potently stimulates the release of norepinephrine (IC50 = 39.4 nM), with less effect on the release of dopamine and serotonin (IC50s = 262 and 3,511 nM, respectively).2 Primarily through these actions, phentermine suppresses appetite and augments fat metabolism, supporting usefulness in ameliorating obesity.3,4
1.Lewin, A.H., Nacarro, H.A., and Mascarella, S.W.Structure-activity correlations for β-phenethylamines at human trace amine receptor 1Bioorganic & Medicinal Chemistry16(15)7415-7423(2008) 2.Rothman, R.B., Baumann, M.H., Dersch, C.M., et al.Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotoninScience39(1)32-41(2001) 3.Li, Z., Maglione, M., Tu, W., et al.Meta-analysis: Pharmacologic treatment of obesityAnnals of Internal Medicine142532-546(2005) 4.Manning, S., Pucci, A., and Finer, N.Pharmacotherapy for obesity: Novel agents and paradigmsTher.Adv.Chronic Dis.5(3)135-148(2014)
| Cas No. | 1330236-21-9 | SDF | |
| Canonical SMILES | NC(C)(C)CC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H].Cl | ||
| 分子式 | C10H10D5N•HCl | 分子量 | 190.7 |
| 溶解度 | 储存条件 | -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.2438 mL | 26.2192 mL | 52.4384 mL |
| 5 mM | 1.0488 mL | 5.2438 mL | 10.4877 mL |
| 10 mM | 0.5244 mL | 2.6219 mL | 5.2438 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。